ATAtossa Therapeutics, Inc. ATOS · NASDAQ
$2.60 -4.41% (-$0.12)
- Market cap
- $27.1M
- Enterprise value
- $1.05M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -146.3%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.28
- Free float
- 98.5%
About the company
Atossa Therapeutics, Inc. (ATOS) is a biotechnology company focused on the development and commercialization of drugs and therapies in the fields of oncology and women's health. The company concentrates on researching new medications and diagnostic methods aimed at the prevention and treatment of various types of cancer, including breast cancer. Atossa Therapeutics also develops innovative treatments and therapeutic approaches to enhance women's health. Shares of Atossa Therapeutics, Inc. (ATOS) can be an interesting choice for investors tracking the biotechnology sector and the development of drugs and therapies.
Sector
Healthcare
Industry
Biotechnology
CEO
Steven C. Quay
Employees
16
Headquarters
Seattle
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number